— Know what they know.
Not Investment Advice

OGN NYSE

Organon & Co.
1W: -0.1% 1M: +0.1% 3M: +1.6% YTD: +90.4% 1Y: +50.4% 3Y: -3.4% 5Y: -52.4%
$13.75
+0.01 (+0.07%)
 
Weekly Expected Move ±0.5%
$14 $14 $14 $14 $14
NYSE · Healthcare · Drug Manufacturers - General · Tech Score Neutral · Power 52 · $3.6B mcap · 261M float · 0.992% daily turnover · Short 46% of daily vol
Credit Risk of going bust: higher than 87% of companies Debt: 70.3% of company value Bonds: $567.6M held by 309 funds, 116 bp over Treasuries → details ▾
Of US companies ranked in the second-riskiest tenth, about 1 in 87 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $2.24 (down 84%), Organon & Co. would be worth roughly what it owes.
Total debt $8.55B against a stock market value of $3.61B.
Distance to default 1.98 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $4.31B (short-term plus half of long-term), stock volatility 62.2%; Altman Z 1.25. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.

📊 Key Metrics

TTM
$6B
Revenue
-2.5% YoY
$209M
Net Income
-70.1% YoY
$498M
Free Cash Flow
+3.3% YoY
54.4%
Gross Margin
20.7%
Op. Margin
6.9%
Net Margin

💰 Income Flow

How revenue becomes profit

💵 Cash Flow

Where cash goes

🏦 Balance Sheet

Assets = Liabilities + Equity

📈 Financial Health

Profitability

ROE24.0%
ROA1.6%
ROIC6.0%

Valuation

P/E17.4
P/B3.6
EV/EBITDA8.5

Leverage

Debt/Equity8.50
Current Ratio1.95
Interest Cov.2.0x

Quality Scores

Piotroski F5/9
Altman Z1.26
Beneish M-2.71

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms